Principia Biopharma Inc (PRNB)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

220 EAST GRAND AVENUE SOUTH SAN FRANCISCO, CA 94080

Principia Biopharma Inc. operates as a clinical stage biopharmaceutical company. The Company offers reversible covalent small molecule drugs for the treatment of cancers. Principia Biopharma serves patients in the United States.

Data as of 2020-08-09
Market Cap3.036 Billion Shares Outstanding33.209 Million Avg 30-day Volume638.633 Thousand
P/E Ratio Dividend Yield EPS-2.52
Price/Sales Price cash flow ratio48.7 Price free cash flow ratio-44.9
Book Value9.98 Price to Tangible Book9.21 Alpha0.06
Short Interest Ratio % Short Interest to Float R-squared0.069385
BETA0.803489 52-week High/Low95.15 / 25.35 Stddev0.181867
View SEC Filings from PRNB instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 7 5 (0.33%)
13F Filers holding this stock: 117 45 (2.95%)
Aggregate 13F shares on 03/31/2020: 30.508 Million 22.858 Million
Aggregate 13F shares on 12/31/2019: 29.134 Million 21.479 Million
Percent change: 4.72% 6.42%
Funds creating new positions: 20 10
Funds Adding to an existing position: 40 13
Funds closing out their position: 18 10
Funds reducing their position: 44 18
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding PRNB (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding PRNB BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

49 Thousand total shares from 14 transactions

Exercise Derivative Conversion (M)

43.5 Thousand total shares from 5 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

GOLDSTEIN DAVID M CHIEF SCIENTIFIC OFFICER

  • Officer
31,739 2020-08-10 5

USMAN NASSIM PRESIDENT & CEO

  • Officer
  • Director
21,216 2020-08-10 0

GLAXOSMITHKLINE PLC

  • 10% Owner
4,626,389 2020-07-24 1

BAKER BROS. ADVISORS LP

BAKER BROS. ADVISORS (GP) LLC

BAKER FELIX

BAKER JULIAN

  • 10% Owner
0 2020-07-20 0

BECKER DANIEL J.

  • Director
  • 10% Owner
2,601,773 2020-07-17 4

THOMAS DOLCA CHIEF MEDICAL OFFICER

  • Officer
1,826 2020-07-15 3

GEORGE SIMEON

  • Director
0 2020-07-09 2

COLOWICK ALAN

  • Director
0 2020-07-01 3

AKKARAJU SRINIVAS

  • Director
1,433,943 2020-07-01 0

BABLER MARTIN PRESIDENT, CEO

  • Officer
  • Director
58,344 2020-06-23 4

MACHADO PATRICK

  • Director
0 2020-06-23 1

THOMPSON PETER A.

  • Director
  • 10% Owner
0 2020-06-17 0

WOLFF STEFANI CHIEF DEVELOPMENT OFFICER

  • Officer
19,096 2020-06-15 6

HARDIMAN ROY C. CHIEF BUSINESS OFFICER

  • Officer
119,677 2020-06-12 5

SMITHER JOHN W CHIEF FINANCIAL OFFICER

  • Officer
123,840 2020-06-11 0

TOMASELLO SHAWN

  • Director
0 2020-06-08 4

LIN SHAO-LEE

  • Director
0 2020-06-04 1

CHAI CHRISTOPHER Y CHIEF FINANCIAL OFFICER

  • Officer
6,841 2020-05-19 3

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP IV LLC

  • 10% Owner
15,786,967 2020-04-14 0

NEW LEAF VENTURES II, L.P.

NEW LEAF VENTURE ASSOCIATES II, L.P.

NEW LEAF VENTURE MANAGEMENT II, L.L.C.

NEW LEAF BIOPHARMA OPPORTUNITIES II, L.P.

NEW LEAF BPO ASSOCIATES II, L.P.

NEW LEAF BPO MANAGEMENT II, L.L.C

  • 10% Owner
2,325,713 2019-08-13 0

MORGENTHALER VENTURE PARTNERS IX LP

MORGENTHALER MANAGEMENT PARTNERS IX, LLC

  • 10% Owner
No longer subject to file 2018-11-16 0

GOURLAY STEVE CHIEF MEDICAL OFFICER

  • Officer
107,857 2018-09-18 0

SOFINNOVA VENTURE PARTNERS VIII, L.P.

SOFINNOVA MANAGEMENT VIII, L.L.C.

HEALY JAMES

POWELL MICHAEL

MEHRA ANAND

  • 10% Owner
2,038,208 2018-09-18 0

SHUSTER LEWIS

  • Director
0 2018-09-13 0

SHUSTER LEWIS

SHUSTER LEWIS

  • Director
0 2018-09-13 0

AKKARAJU SRINIVAS

AKKARAJU SRINIVAS

  • Director
0 2018-09-13 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

GOLDSTEIN DAVID M - Officer CHIEF SCIENTIFIC OFFICER

2020-08-10 M 3,553 d 12,960 31,739.00 direct

GOLDSTEIN DAVID M - Officer CHIEF SCIENTIFIC OFFICER

2020-08-10 S 1,108 $90.99 d 31,839 31,739.00 direct yes

GOLDSTEIN DAVID M - Officer CHIEF SCIENTIFIC OFFICER

2020-08-10 S 700 $86.92 d 36,181 31,739.00 direct yes

GOLDSTEIN DAVID M - Officer CHIEF SCIENTIFIC OFFICER

2020-08-10 M 2,447 $3.00 a 34,186 31,739.00 direct

GOLDSTEIN DAVID M - Officer CHIEF SCIENTIFIC OFFICER

2020-08-10 M 2,447 d 0 31,739.00 direct

GOLDSTEIN DAVID M - Officer CHIEF SCIENTIFIC OFFICER

2020-08-10 S 700 $89.68 d 32,947 31,739.00 direct yes

GOLDSTEIN DAVID M - Officer CHIEF SCIENTIFIC OFFICER

2020-08-10 S 858 $86.11 d 36,881 31,739.00 direct yes

GOLDSTEIN DAVID M - Officer CHIEF SCIENTIFIC OFFICER

2020-08-10 S 100 $93.34 d 31,739 31,739.00 direct yes

GOLDSTEIN DAVID M - Officer CHIEF SCIENTIFIC OFFICER

2020-08-10 S 2,534 $88.40 d 33,647 31,739.00 direct yes

GOLDSTEIN DAVID M - Officer CHIEF SCIENTIFIC OFFICER

2020-08-10 M 3,553 $3.18 a 37,739 31,739.00 direct

THOMAS DOLCA - Officer CHIEF MEDICAL OFFICER

2020-07-15 M 15,000 $23.77 a 16,826 1,826.00 direct

THOMAS DOLCA - Officer CHIEF MEDICAL OFFICER

2020-07-15 M 15,000 d 183,057 1,826.00 direct

THOMAS DOLCA - Officer CHIEF MEDICAL OFFICER

2020-07-15 S 15,000 $80.07 d 1,826 1,826.00 direct yes

COLOWICK ALAN - Director

2020-07-01 M 7,500 $4.54 a 7,500 0.00 direct

COLOWICK ALAN - Director

2020-07-01 M 7,500 d 47,724 0.00 direct

COLOWICK ALAN - Director

2020-07-01 S 7,500 $60.00 d 0 0.00 direct yes

BABLER MARTIN - Director - Officer PRESIDENT, CEO

2020-06-23 S 11,983 $61.82 d 3,312 58,344.00 direct yes

BABLER MARTIN - Director - Officer PRESIDENT, CEO

2020-06-23 M 15,000 d 85,728 58,344.00 direct

BABLER MARTIN - Director - Officer PRESIDENT, CEO

2020-06-23 S 515 $60.32 d 15,295 58,344.00 direct yes

BABLER MARTIN - Director - Officer PRESIDENT, CEO

2020-06-23 S 2,502 $62.38 d 810 58,344.00 direct yes

BABLER MARTIN - Director - Officer PRESIDENT, CEO

2020-06-23 M 15,000 $3.00 a 15,810 58,344.00 direct

WOLFF STEFANI - Officer CHIEF DEVELOPMENT OFFICER

2020-06-15 S 400 $59.89 d 24,200 19,096.00 direct yes

WOLFF STEFANI - Officer CHIEF DEVELOPMENT OFFICER

2020-06-15 S 100 $61.37 d 19,096 19,096.00 direct yes

WOLFF STEFANI - Officer CHIEF DEVELOPMENT OFFICER

2020-06-15 S 5,004 $60.81 d 19,196 19,096.00 direct yes
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments